Sanofi-Aventis SA (SNYNF/SNYNF.PK) Penny Investment Summary:

Sanofi-Aventis, a pharmaceutical company, contributes to enhancing life by providing an offering of medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company has products in the areas of thrombosis, cardiovascular, metabolic diseases, oncology, central nervous system, internal medicine, and vaccines. Its primary medicines include Lovenox/Clexane, Plavix/Iscover, Aprovel/Avapro/Karvea, Tritace/Triatec/Delix/Altace, Lantus, Amaryl/Amarel/Solosa, Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. The company?s vaccines principally include pediatric combination and poliomyelitis vaccines, influenza vaccines, meningitis/pneumonia vaccines, adult and adolescent booster vaccines, and travel and endemic vaccines. It has collaboration agreements principally with Novozymes, Dyax Corp., Oxford BioMedica, Regeneron, IDM, Zealand Pharma, UCB, and Crucell N.V., as well as partners, including Immunogen, Coley, Wayne State University, Innogenetics, Inserm, and Micromet Inc. The company also has an agreement with Drugs For Neglected Diseases Initiative (dndi) for the development, manufacturing, and distribution of fexinidazole, a drug for the treatment of human African trypanosomiasis; and a licensing agreement with Wellstat Therapeutics Corporation to develop, manufacture, and commercialize PN2034, an oral insulin sensitizer for the treatment of Type II diabetes. In addition, the company has interest in Merial Limited, an animal health company that provides a range of products to enhance the health, well-being, and performance of animals. It has a strategic antibody collaboration agreement with Regeneron Pharmaceuticals Inc. to discover, develop, and commercialize human therapeutic monoclonal antibodies. Sanofi-Aventis was founded in 1970 and is headquartered in Paris, France.